ASHBURN, Va., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that its NETHERTON NOW awareness campaign has surpassed a major milestone, achieving more than one million video views and over 14 million impressions. Launched to give patients, families, and experts a greater voice, NETHERTON NOW has become a global platform shining a spotlight on the pai ...

Core Insights - Quoin Pharmaceuticals has released the second episode of its "Living with Netherton" video series, featuring the story of 79-year-old Norma Coles, who was diagnosed with Netherton Syndrome decades after her initial evaluation [1][2] - The campaign aims to raise awareness and support for individuals affected by Netherton Syndrome, highlighting the challenges faced by patients, including misdiagnosis and lack of treatment options [2][4] - Quoin's lead product candidate, QRX003, is currently undergoing clinical trials, with the goal of becoming the first FDA-approved treatment for Netherton Syndrome [5][6] Company Overview - Quoin Pharmaceuticals is a late clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases [1][7] - The company has a pipeline that includes four products targeting various rare conditions, including Netherton Syndrome, Peeling Skin Syndrome, and others [7] - Quoin is committed to addressing unmet medical needs and improving the quality of life for patients and their families [7] Product Development - QRX003 is a topical lotion designed to address the skin barrier issues associated with Netherton Syndrome by promoting a normalized skin-shedding process [6] - Initial data from ongoing clinical trials of QRX003 show promising results, including improvements in skin healing and reductions in inflammation and pruritus [5] - The company aims to complete the development of QRX003 to provide a transformative treatment option for patients who have long awaited effective therapies [5][6]

Core Insights - Quoin Pharmaceuticals has released the second episode of its "Living with Netherton" video series, featuring a 79-year-old patient, Norma Coles, who has lived with Netherton Syndrome for decades, highlighting the need for awareness and treatment [1][2][4] - The company aims to raise awareness and improve education regarding Netherton Syndrome, which currently has no FDA-approved treatment, emphasizing the urgency for effective therapeutic options [2][5] Company Overview - Quoin Pharmaceuticals is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases [1][7] - The company is committed to addressing unmet medical needs and has a pipeline that includes four products targeting various rare conditions, including Netherton Syndrome [7] Product Development - Quoin's lead product candidate, QRX003, is currently undergoing evaluation in four clinical trials for the treatment of Netherton Syndrome, with initial data showing improvements in skin healing and quality of life [5][6] - QRX003 is a topical lotion designed to normalize skin-shedding processes and strengthen the skin barrier, addressing the underlying issues of Netherton Syndrome [6] Campaign and Advocacy - The NETHERTON NOW campaign is central to Quoin's efforts to raise awareness and support for individuals affected by Netherton Syndrome, sharing real patient experiences to foster understanding [4][5] - The company emphasizes the importance of patient stories, like that of Norma Coles, to illustrate the challenges faced by those living with this rare genetic disorder [2][5]